Lyssa J. Weible
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lyssa J. Weible has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Kayode K. Ojo
Department of Medicine, Center for Emerging and Re-Emerging Infectious Diseases, University of Washington, Seattle, WA 98109-4766, USA
2 shared publications - Alexandra Kolas
Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA
1 shared publication - Alexis Cotto-Rosario
Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA
1 shared publication - Ana A. Weil
Department of Medicine, University of Washington, Seattle, USA
1 shared publication - Ana Carolina Ribeiro Gomes Maia
Departamento de Bioquímica, Laboratório de Estrutura e Função de Proteínas, Instituto de Ciências Biológicas, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil
1 shared publication - Chidiebere N. Onoh
Department of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA
1 shared publication
Latest Publications
- Open Access
- 4 November 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (11) , 2527
Norditerpene Natural Products from Subterranean Fungi with Anti-Parasitic Activity
Cryptosporidium is a waterborne gastrointestinal parasite that causes diarrheal disease worldwide. Currently, there are no effective therapeutics to treat cryptosporidiosis. Since natural products are a known source of anti-parasitic compounds, we screened a library of extracts and pure compounds isolated from bacteria and fungi collected from subterranean environments for anti-Cryptosporidium activity. Seven norditerpene lactones isolated from the fungus Oidiodendron truncatum collected from the Soudan Iron mine in Minnesota showed potent activity and were further tested to identify the most active compounds. The availability of a diverse suite of natural structural analogs with varying activities allowed us to determine some structure–activity relationships for both anti-parasitic activity and cytotoxicity. The two most potent compounds, oidiolactones A and B, had EC50s against C. parvum of 530 and 240 nM, respectively, without cytotoxicity to host cells. Both compounds also inhibited the related parasite Toxoplasma gondii. Oidiolactone A was active against asexual, but not sexual, stages of C. parvum, and killed parasites within 8 h of treatment. This compound reduced C. parvum infection by 70% in IFNγ−/− mice, with no signs of toxicity. The high potency, low cytotoxicity, and in vivo activity combined with high production and synthetic accessibility make these oidiolactones attractive scaffolds for the development of new anti-Cryptosporidium therapeutics.
- 4 November 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (11) , 2527
Open AccessNorditerpene Natural Products from Subterranean Fungi with Anti-Parasitic Activity
Cryptosporidium is a waterborne gastrointestinal parasite that causes diarrheal disease worldwide. Currently, there are no effective therapeutics to treat cryptosporidiosis. Since natural products are a known source of anti-parasitic compounds, we screened a library of extracts and pure compounds isolated from bacteria and fungi collected from subterranean environments for anti-Cryptosporidium activity. Seven norditerpene lactones isolated from the fungus Oidiodendron truncatum collected from the Soudan Iron mine in Minnesota showed potent activity and were further tested to identify the most active compounds. The availability of a diverse suite of natural structural analogs with varying activities allowed us to determine some structure–activity relationships for both anti-parasitic activity and cytotoxicity. The two most potent compounds, oidiolactones A and B, had EC50s against C. parvum of 530 and 240 nM, respectively, without cytotoxicity to host cells. Both compounds also inhibited the related parasite Toxoplasma gondii. Oidiolactone A was active against asexual, but not sexual, stages of C. parvum, and killed parasites within 8 h of treatment. This compound reduced C. parvum infection by 70% in IFNγ−/− mice, with no signs of toxicity. The high potency, low cytotoxicity, and in vivo activity combined with high production and synthetic accessibility make these oidiolactones attractive scaffolds for the development of new anti-Cryptosporidium therapeutics.
- Open Access
- 15 September 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (9) , 2323
The Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children
Cryptosporidium species and Giardia duodenalis are infectious intestinal protozoan pathogens that cause alarming rates of morbidity and mortality worldwide. Children are more likely to have clinical symptoms due to their less developed immune systems and factors such as undernutrition, especially in low- and middle-income countries. The severity of the symptoms and clinical manifestations in children may vary from asymptomatic to life-threatening depending on the Cryptosporidium species/G. duodenalis strains and the resulting complex stepwise interactions between the parasite, the host nutritional and immunologic status, and the gut microbiome profile. Structural damages inflicted by both parasites to epithelial cells in the large and small intestines could severely impair children’s gut health, including the ability to absorb nutrients, resulting in stunted growth, diminished neurocognitive development, and other long-term effects. Clinically approved cryptosporidiosis and giardiasis drugs have broad antimicrobial effects that have incomprehensible impacts on growing children’s gut health.
- 15 September 2023
- Published by MDPI AG in Microorganisms
- Vol. 11 (9) , 2323
Open AccessThe Gut-Wrenching Effects of Cryptosporidiosis and Giardiasis in Children
Cryptosporidium species and Giardia duodenalis are infectious intestinal protozoan pathogens that cause alarming rates of morbidity and mortality worldwide. Children are more likely to have clinical symptoms due to their less developed immune systems and factors such as undernutrition, especially in low- and middle-income countries. The severity of the symptoms and clinical manifestations in children may vary from asymptomatic to life-threatening depending on the Cryptosporidium species/G. duodenalis strains and the resulting complex stepwise interactions between the parasite, the host nutritional and immunologic status, and the gut microbiome profile. Structural damages inflicted by both parasites to epithelial cells in the large and small intestines could severely impair children’s gut health, including the ability to absorb nutrients, resulting in stunted growth, diminished neurocognitive development, and other long-term effects. Clinically approved cryptosporidiosis and giardiasis drugs have broad antimicrobial effects that have incomprehensible impacts on growing children’s gut health.